Perspective Therapeutics Inc’s filing revealed that its Director HENSON HEIDI acquired Company’s shares for reported $0.1 million on Dec 04 ’24. In the deal valued at $3.85 per share,25,975 shares were bought. As a result of this transaction, HENSON HEIDI now holds 25,975 shares worth roughly $63638.75000000001.
Then, Spoor Johan M. bought 8,000 shares, generating $30,132 in total proceeds. Upon buying the shares at $3.77, the CEO now owns 36,257 shares.
Before that, Williamson Robert F III bought 6,266 shares. Perspective Therapeutics Inc shares valued at $22,814 were divested by the Director at a price of $3.64 per share. As a result of the transaction, Williamson Robert F III now holds 430,058 shares, worth roughly $1.05 million.
H.C. Wainwright initiated its Perspective Therapeutics Inc [CATX] rating to a Buy in a research note published on March 13, 2025; the price target was $10. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early March with a ‘”a Sector outperform”‘ rating. BofA Securities also remained covering CATX and has decreased its forecast on November 25, 2024 with a “Neutral” recommendation from previously “Buy” rating. UBS started covering the stock on October 24, 2024. It rated CATX as “a Buy”.
Price Performance Review of CATX
On Tuesday, Perspective Therapeutics Inc [AMEX:CATX] saw its stock fall -5.77% to $2.45. Over the last five days, the stock has lost -2.00%. Perspective Therapeutics Inc shares have fallen nearly -23.20% since the year began. Nevertheless, the stocks have fallen -77.10% over the past one year. While a 52-week high of $19.05 was reached on 01/24/25, a 52-week low of $2.32 was recorded on 03/04/25. SMA at 50 days reached $3.11, while 200 days put it at $8.90.
Levels Of Support And Resistance For CATX Stock
The 24-hour chart illustrates a support level at 2.34, which if violated will result in even more drops to 2.24. On the upside, there is a resistance level at 2.59. A further resistance level may holdings at 2.72. The Relative Strength Index (RSI) on the 14-day chart is 37.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.00%. Stochastics %K at 45.33% indicates the stock is a holding.
How much short interest is there in Perspective Therapeutics Inc?
A steep rise in short interest was recorded in Perspective Therapeutics Inc stocks on 2025-02-28, growing by 0.49 million shares to a total of 5.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 5.42 million shares. There was a rise of 8.33%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 01, 2024 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
